comprehensive -WSS

comprehensive

author：focus 2025-09-06 01:58:42 - browse：4

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： FDA panel to weigh safety of artificial wombs for preterm births

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Surprise medical billing ban raises prices elsewhere

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Why the drug industry's warnings on the IRA's impact fall short

As AI regulations shape up, health tech startups beg for clarity

MD Anderson's Padmanee Sharma responds to research credit suit

focus

comprehensive

entertainment

Psychedelics group wrestles with new pharma identity

In 'major milestone,' FDA approves first cell therapy for solid tumors

The cancer drug shortage isn’t new — and neither are the solutions

As AI regulations shape up, health tech startups beg for clarity

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Akili changes sales model for its ADHD video game treatment

Duchenne breakthrough therapy leaves behind pioneering families

Information blocking fines are now fair game in health care

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA warns medical device makers about rise in fabricated data

entertainment

Fed up with FDA, ALS advocates consider a take

Akili changes sales model for its ADHD video game treatment

Grad students accuse University of California of wage theft

David Liu startup to focus on CRISPR delivery

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Free Covid tests will again be offered to all U.S. households

hotspot

focus

explore

Wikipedia